


Clean Version of Amended Claims

1 (Original). A compound of formula (I)



wherein

- one of X and Y is silicon, and the other is carbon or silicon;
- Z is oxygen, sulphur or -N(R)-, wherein R is hydrogen or alkyl;
- R¹ is hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy or cycloalkyl; and
- R² is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -alkyl-cycloalkyl, -alkyl-heterocycloalkyl, -alkyl-aryl or -alkyl-heteroaryl;
- or a pharmaceutically acceptable salt thereof.

2 (Currently amended). The compound according to claim 1, wherein X and Y are each silicon.

3 (Currently amended). The compound according to claim 1, wherein Z is oxygen.

4 (Currently amended). The compound according to claim 1, wherein R¹ is hydrogen or alkyl.

5 (Currently amended). The compound according to claim 4, wherein R¹ is methyl.

6 (Currently amended). The compound according to claim 1, wherein R² is aryl, -CH₂-cycloalkyl, -CH₂-aryl, -CH₂-heterocycloalkyl or -CH₂-heteroaryl.


7 (Currently amended). The compound according to claim 6, wherein R² is optionally substituted phenyl.

8 (Currently amended). The compound according to claim 7, wherein R^2 is phenyl substituted with one, two or three alkoxy groups.

9 (Currently amended). The compound according to claim 1, which is 5-[(3,5,5,8,8-pentamethyl-5,8-disila-5,6,7,8-tetrahydro-2-naphthyl)methyl]-*N*-(2,4,6-trimethoxyphenyl)furan-2-carboxamide.

10 (Canceled).

11 (Currently amended). A pharmaceutical composition comprising a compound of formula (I)



wherein

one of X and Y is silicon, and the other is carbon or silicon;

Z is oxygen, sulphur or $-N(R)-$, wherein R is hydrogen or alkyl;


R^1 is hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy or cycloalkyl; and

R^2 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -alkyl-cycloalkyl, -alkyl-heterocycloalkyl, -alkyl-aryl or -alkyl-heteroaryl;

or a pharmaceutically acceptable salt thereof;

and a pharmaceutically acceptable diluent or carrier.

12 (Currently amended). A method for the treatment or prevention of a disease or condition associated with GnRH wherein said method comprises administering a compound of formula (I)



wherein

one of X and Y is silicon, and the other is carbon or silicon;

Z is oxygen, sulphur or $-N(R)-$, wherein R is hydrogen or alkyl;

R^1 is hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy or cycloalkyl; and

R^2 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, -alkyl-cycloalkyl, -alkyl-heterocycloalkyl, -alkyl-aryl or -alkyl-heteroaryl;

or a pharmaceutically acceptable salt thereof;

to a patient in need of such treatment.

13 (Currently amended). The method according to claim 12, for the treatment or prevention of progression of cancer.

14 (Currently amended). The method according to claim 13, for leukaemia therapy.

15 (Currently amended). The method according to claim 12, for the treatment or prevention of a fertility disorder.

16 (Currently amended). The method according to claim 12, for the treatment or prevention of HIV infection or AIDS.

17 (Currently amended). The method according to claim 12, for the treatment or prevention of Alzheimer's disease.

18 (Currently amended). The method according to claim 12, for the treatment or prevention of fibrosis.

19 (Currently amended). The method according to claim 12, for the treatment or prevention of endometriosis.

20 (Currently amended). The method according to claim 12, for the treatment or prevention of uterine fibroids.

21 (Currently amended). The method according to claim 12, for the treatment or prevention of uterine leiomyoma.